Figure 3.
Primary and secondary outcomes by ADRB2 Gly16-Glu27-523C haplotype and antihypertensive drug therapy. *Crude incidence per 1,000 patient years. †Includes only patients ever exposed to atenolol (94% in atenolol strategy). ‡Hazard ratios based on reduced model adjusted for age, sex, and race/ ethnicity. MI, myocardial infarction; SR, sustained release.